Get the Stockscreener App
4.04
3.35%
-0.14
Oramed Pharmaceuticals Inc stock is traded at $4.04, with a volume of 226.89K.
It is down -3.35% in the last 24 hours and up +9.19% over the past month.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.
See More
Previous Close:
$4.18
Open:
$4.18
24h Volume:
226.89K
Relative Volume:
0.80
Market Cap:
$165.34M
Revenue:
$2.00M
Net Income/Loss:
$109.16M
P/E Ratio:
1.5638
EPS:
2.5835
Net Cash Flow:
$-9.11M
1W Performance:
-12.17%
1M Performance:
+9.19%
6M Performance:
+17.78%
1Y Performance:
+90.57%
1-Day Range:
$4.035
$4.22
1-Week Range:
$4.035
$4.73
52-Week Range:
$1.975
$5.19
Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile
Name
Oramed Pharmaceuticals Inc
Sector
Industry
Phone
646-844-1164
Address
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
Compare ORMP vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORMP
Oramed Pharmaceuticals Inc
|
4.04 | 165.34M | 2.00M | 109.16M | -9.11M | 2.5835 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-12-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Feb-18-22 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-20-21 | Initiated | Canaccord Genuity | Buy |
| Feb-09-21 | Initiated | National Securities | Buy |
| Dec-03-20 | Initiated | Alliance Global Partners | Buy |
| Mar-11-20 | Initiated | Aegis Capital | Buy |
| Sep-11-19 | Initiated | Ladenburg Thalmann | Buy |
| Dec-11-17 | Resumed | B. Riley FBR, Inc. | Buy |
| May-26-16 | Reiterated | FBR Capital | Outperform |
| Dec-01-15 | Reiterated | H.C. Wainwright | Buy |
| Nov-19-15 | Initiated | FBR Capital | Outperform |
| Apr-13-15 | Resumed | MLV & Co | Buy |
| Jan-30-14 | Reiterated | Aegis Capital | Buy |
| Jan-08-14 | Reiterated | Aegis Capital | Buy |
| Jan-08-14 | Initiated | MLV & Co | Buy |
| Dec-03-13 | Initiated | Aegis Capital | Buy |
View All
Oramed Pharmaceuticals Inc Stock (ORMP) Latest News
Price to sales forward of Oramed Pharmaceuticals Inc. – NASDAQ:ORMP - TradingView
Enterprise value to EBIT forward of Oramed Pharmaceuticals Inc. – NASDAQ:ORMP - TradingView
Oramed Pharmaceuticals highlights oral drug platform as investors assess long-term prospects - ad-hoc-news.de
Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet - AOL.com
Oramed Pharmaceuticals outlines its oral drug strategy as Nasdaq-listed biotech pursues long-term gr - ad-hoc-news.de
Price to earnings forward of Oramed Pharmaceuticals Inc. – NASDAQ:ORMP - TradingView
Oramed Pharmaceuticals stock holds its ground. Investors await the next company update. - ad-hoc-news.de
ORMP News | ORAMED PHARMACEUTICALS INC (NASDAQ:ORMP) - ChartMill
Insider Sell: Avraham Gabay Sells 73,360 Shares of Oramed Pharma - GuruFocus
Oramed Pharmaceuticals COO & Cbo Sold Shares Worth Over $611K - TradingView
Oramed (NASDAQ: ORMP) COO sells 137K shares after option exercise - Stock Titan
ORAMED (NASDAQ: ORMP) CFO executes pre-planned sale of 73,360 shares - Stock Titan
Oramed Pharmaceuticals Incorporated Financial Disclosures & SEC Filings - TradingView
Form 144 ORAMED PHARMACEUTICALS INC. For: 1 July By Investing.com - Investing.com South Africa
137,000 shares flagged for sale by Oramed (NASDAQ: ORMP) in Form 144 - Stock Titan
Oramed (NASDAQ: ORMP) Form 144 notes 93,360 RSU shares on 06/18/2026 - Stock Titan
Oramed Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Oramed Pharm Updates Bylaws, Streamlining Shareholder Actions - TipRanks
Oramed (NASDAQ: ORMP) revises bylaws and restructures Scilex note obligations - Stock Titan
Oramed Pharmaceuticals Inc.(NasdaqCM: ORMP) added to Russell 2000 Index - marketscreener.com
Oramed Pharmaceuticals Inc.(NasdaqCM: ORMP) added to Russell 2000 Value Benchmark - marketscreener.com
BML Investment Holds 2.5% of Oramed (ORMP) in Amended 13G/A - Stock Titan
Oramed Pharmaceuticals Inc.(NasdaqCM: ORMP) added to Russell 3000E Index - marketscreener.com
Oramed Pharmaceuticals Inc.(NasdaqCM:ORMP) added to Russell 2000 Value-Defensive Index - marketscreener.com
Oramed Pharmaceuticals Inc.(NasdaqCM: ORMP) added to Russell 2500 Value Benchmark - marketscreener.com
Oramed Pharmaceuticals Inc.(NasdaqCM:ORMP) added to Russell 3000E Value Benchmark - marketscreener.com
Oramed Pharmaceuticals Incorporated Actuals & Estimates (MUN:OJU1) - TradingView
Oramed Pharmaceuticals Incorporated Actuals & Estimates (DUS:OJU1) - TradingView
These healthcare stocks are combining strong gains with reasonable prices - MSN
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Oramed Releases Letter to Shareholders, Highlighting Russell 200 - GuruFocus
Oramed Pharmaceuticals Incorporated Actuals & Estimates (NASDAQ:ORMP) - TradingView
Oramed's Pivot Pays Off: From Pharma Hopeful to Investment Powerhouse - BriefGlance
Oramed Pharmaceuticals Inc (ORMP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ORMP SEC FilingsOramed Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Daily Brief United States: Tesla , Adobe Systems, Nine Energy Service , Oramed Pharmaceuticals , Olin Corp, Earth Science Tech, Kardigan, Generac Holdings, General Motors, Nucor Corp and more - Smartkarma
ORMP: View Inclusion in Russell Indexes as Positive That Could Raise Awareness in Investment Community - Yahoo Finance
Oramed Pharmaceuticals Inc (ORMP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Oramed Pharmaceuticals Inc (ORMP) Valuation: PE, PB & Fair Value Analysis - TradingKey
Oramed Pharmaceuticals Inc (ORMP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Oramed Pharmaceuticals Inc (ORMP) Institutional Confidence - TradingKey
Oramed Pharmaceuticals Inc (ORMP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Oramed (ORMP) Set to Join Russell 2000 and 3000 Indexes in 2026 - GuruFocus
Oramed Pharmaceuticals Inc (ORMP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Oramed Pharmaceuticals Inc (ORMP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Oramed Pharmaceuticals Inc - TradingKey
Oramed Pharmaceuticals to join Russell 2000, 3000 indexes - Investing.com
Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes - PR Newswire
Oramed (NNDM holder) lifts Nano Dimension stake to 7.2% and opposes proposed deal - Stock Titan
June 2026 Penny Stocks To Watch For Potential Growth - Yahoo Finance
ORMP Q4 2025 Earnings: Surprise Profit as EPS Exceeds Zero EstimateEarnings Momentum Score - dars.gov.et
Oramed Pharmaceuticals Inc Stock (ORMP) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):